-

09:40:51 AM

ERAS Stock News

ERAS - Erasca Inc

06/05/23 4:01 PM

Nasdaq : ERAS

Erasca Provides Update on Clinical Program for ERK Inhibitor ERAS-007 and Refines Pipeline

ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with BRAFm CRC showed a 50% (3/6) response rate (2 cPR, 1 uPR), reinforcing ERAS-007 as a potential best-in-class ERK inhibitor Ongoing clinical programs for naporafenib, ERAS-007, ERAS-601, and ERAS-801 in patients with

RHEA-AI

neutral

06/01/23 8:00 AM

Nasdaq : ERAS

conferences

Erasca to Present at Upcoming Investor Conferences

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will present at the

RHEA-AI

neutral

05/31/23 8:00 AM

Nasdaq : ERAS

conferences

Erasca to Host Virtual Investor Event on Pipeline Updates with a Focus on ERAS-007 ERK Inhibitor

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK

RHEA-AI

neutral

05/25/23 5:00 PM

Nasdaq : ERAS

conferencesclinical trial

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

Triplet of ERAS-007 100 mg BID-QW + encorafenib + cetuximab (EC) in EC-naïve patients with metastatic BRAF V600E-mutated colorectal cancer (CRC) showed a 40% (2/5) response rate; continued evaluation of this combination will focus on EC-naïve patients based on promising initial activity ERAS-007 in

RHEA-AI

neutral

05/16/23 8:00 AM

Nasdaq : ERAS

Erasca Further Strengthens Business Leadership with Two Key Promotions

David Chacko, M.D., previously Erasca’s Chief Financial Officer, has been promoted to the dual position of Chief Financial Officer and Chief Business Officer Nik Chetwyn, Ph.D., previously Erasca’s SVP of Operations, has been promoted to Chief Operating Officer SAN DIEGO, May 16, 2023 (GLOBE

RHEA-AI

neutral

05/15/23 4:01 PM

Nasdaq : ERAS

earnings

Erasca Reports First Quarter 2023 Financial Results and Business Updates

Publication of promising Phase 1b data in Journal of Clinical Oncology supports plans for pivotal Phase 3 SEACRAFT-2 trial for naporafenib in patients with NRASm melanoma expected to initiate in H1 2024; dosing of the first patient in Phase 1b SEACRAFT-1 trial in patients with RAS Q61X tissue

RHEA-AI

neutral

05/02/23 8:00 AM

Nasdaq : ERAS

conferences

Erasca to Present at the Bank of America Securities 2023 Health Care Conference

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that management will participate in

RHEA-AI

neutral

05/01/23 8:00 AM

Nasdaq : ERAS

Erasca Granted FDA Fast Track Designation for CNS-Penetrant EGFR Inhibitor ERAS-801 in Patients with Glioblastoma

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision

RHEA-AI

neutral

04/26/23 5:00 PM

Nasdaq : ERAS

Erasca Announces Two Poster Presentations at the 2023 ASCO Annual Meeting

Erasca, Inc. (Nasdaq: ERAS), a clinical-stage

RHEA-AI

neutral

04/25/23 8:00 AM

Nasdaq : ERAS

clinical trial

Erasca Announces Publication of Promising Clinical Data Supporting the Therapeutic Potential of Naporafenib in Combination with Trametinib in NRAS-Mutant Melanoma

Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients 47% ORR, 5.5 months mPFS observed with preferred combination dose of naporafenib 200 mg BID plus trametinib 1 mg QD Dosing of first patient in Erasca’s pivotal Phase 3 trial in NRASm melanoma

RHEA-AI

neutral

1 2 3 4 5 6 Next

ERAS Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.erasca.com
CeoJonathan E. Lim
Security nameErasca Inc
Issue typecs
SectorManufacturing
Sic code2834

About Erasca Inc

At Erasca, its name is its mission: To erase cancer. Erasca is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company was co-founded by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway for the treatment of cancer. Erasca has assembled what the company believes to be the deepest RAS/MAPK pathway-focused pipeline in the industry. Erasca believes its team’s capabilities and experience, further guided by its scientific advisory board which includes the world’s leading experts in the RAS/MAPK pathway, uniquely position the company to achieve its bold mission of erasing cancer.